# Stoke Therapeutics, Inc. (STOK) FY2026 Q2 P&L / Income Statement

- Company: Stoke Therapeutics, Inc. (STOK)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001193125-26-330557
- Page: https://plicit.ai/financials/stok/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/stok-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Arrangement

Income statement for 2026-04-01 through 2026-06-30. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 9,325,000 US dollars
- **Total operating expenses**: 74,754,000 US dollars
- **(Loss) income from operations**: negative 65,429,000 US dollars
- **Total other income (expense)**: 3,811,000 US dollars
- **(Loss) income before income taxes**: negative 61,618,000 US dollars
- **Provision for income taxes**: 0 US dollars
- **Net (loss) income**: negative 61,618,000 US dollars
- **Acadia Agreement**: 2,800,000 US dollars
- **Biogen License Agreement**: 6,500,000 US dollars
- **Undisclosed (calculated)**: 25,000 US dollars
- **Total operating expenses**: 74,754,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.